Healthcare shares are flat to higher in pre-market trade.
Amicus Therapeutics (
), a biopharmaceutical company engaged in therapies for rare and
orphan diseases, has entered a collaboration with Biogen Idec (
) to discover, develop and commercialize novel small molecules for
the treatment of Parkinson's disease.
FOLD is up 19% at $3.03 in pre-market trade; BIIB is up 0.7% at
The collaboration will build upon preclinical studies at Amicus
and independent published research that suggest increasing activity
of the lysosomal enzyme glucocerobrosidase in the brain may correct
alpha-synuclein pathology and other deficits associated with
And NuPathe (
) says it received a U.S. patent related to its iontophoretic patch
that uses a two-stage delivery sequence to transdermally deliver
sumatriptan. This, and other proprietary technology, is
incorporated into PATH's lead product, ZECUITY, the first and only
FDA approved patch for migraine. PATH is flat at $2.59 in
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.